Breast cancer and obesity: in vitro interferences between adipokines and proangiogenic features and/or antitumor therapies?

PLoS One. 2013;8(3):e58541. doi: 10.1371/journal.pone.0058541. Epub 2013 Mar 15.

Abstract

Obesity is now considered as a risk factor for breast cancer in postmenopausal women. Adipokine levels are modulated in obesity, and may play a role in carcinogenesis. Moreover, obesity increases risk of cancer mortality. Here, we hypothesized that this increase could be due to a modification in angiogenesis, capital event in the development of metastases, and/or in effectiveness of cancer treatments. To test these assumptions, following a same experimental design and simultaneously the effects of leptin and adiponectin on angiogenesis were investigated, and the impact of hyperleptinemia on anticancer drug effectiveness was measured in physiological and obesity situations. Focusing on angiogenesis, the proliferation of endothelial cells (HUVEC), which expressed leptin and adiponectin receptors, was stimulated by leptin and inhibited by adiponectin. Both adipokines globally reduced apoptosis and caspase activity. Leptin increased migration whereas adiponectin decreased migration, and leptin enhanced the area of the tubes formed by HUVEC cells while adiponectin inhibited their formation. MCF7 and MDA-MB-231 cells treated with leptin secreted more VEGF than untreated cells, whereas adiponectin treatment inhibited VEGF secretion. Finally, MCF7 cells pre-treated with leptin were more invasive than untreated cells. This effect was not reproduced in MDA-MB-231 cells. In the MCF7 breast cancer cell line, leptin could induce cell proliferation and reduced the efficacy of all breast cancer therapies (tamoxifen, 5-fluorouracil, taxol and vinblastin). These results suggest that, in obesity situation, leptin- in contrast to adiponectin - may promote tumor invasion and angiogenesis, leading to metastases 'apparition, and reduce treatment efficacy, which could explain the increased risk of cancer mortality in cases of overweight. The evidence suggests adipokines influence breast cancer issue and could play a significant role, especially in obese patients for which hyperleptinemia, hypoadiponectinemia and increased metastatic potential are described.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adiponectin / metabolism*
  • Adiponectin / pharmacology
  • Antineoplastic Agents / pharmacology*
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / metabolism
  • Breast Neoplasms* / pathology
  • Cell Line, Tumor
  • Cell Movement / drug effects
  • Female
  • Human Umbilical Vein Endothelial Cells
  • Humans
  • Leptin / metabolism*
  • Leptin / pharmacology
  • Neoplasm Invasiveness
  • Neoplasm Proteins / metabolism*
  • Neovascularization, Pathologic / drug therapy
  • Neovascularization, Pathologic / metabolism*
  • Neovascularization, Pathologic / pathology
  • Obesity / metabolism*
  • Obesity / pathology
  • Receptors, Leptin / metabolism
  • Vascular Endothelial Growth Factor A / metabolism*

Substances

  • ADIPOQ protein, human
  • Adiponectin
  • Antineoplastic Agents
  • LEPR protein, human
  • Leptin
  • Neoplasm Proteins
  • Receptors, Leptin
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A

Grants and funding

This study received financial support from the ‘Ligue Contre le Cancer’ and from CLARA (Canceropôle Lyon Auvergne Rhône-Alpes, France). Virginie Dubois is supported by a fellowship from the French Ministry of Research and Technology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.